NEW YORK (GenomeWeb) – Mimetas, a developer of 3D disease- and tissue-modelling technologies, today said that it has raised $5.2 million in a private financing round to further develop its organ-on-a-chip technology platform.
Jos Joore, co-founder and chief business officer of the Leiden, Netherlands-based firm, said in a statement that the funds would be used to scale up production of Mimetas' OrganoPlates, which are used for 3D cell culture, and to "strengthen our activities in predictive preclinical model development."
Mimetas currently has a range of disease, toxicology, and ADME models in its pipeline under development or in validation phase.
The company said it received funding from venture capital firms Zeeuws Investerings Fonds and Participatiemaatschapij Oost Nederland.
Mimetas recently received $1.6 million in funding to develop a kidney-on-a-chip for toxicological applications. It will collaborate with Roche, Pfizer, GlaxoSmithKline, Radboud University Nijmegen Medical Center, and the University of Applied Sciences and Arts Northwestern Switzerland on the project.